Xyrem REMS Grudgingly Approved; FDA Worries About Blocked Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
Single-pharmacy distribution system for Jazz’s narcolepsy treatment isn’t necessarily needed, FDA says, even as it clears that risk management plan.
You may also be interested in...
REMS And Generics: GPhA Needs Legislation, Continues Education
GPhA says congressional action is only remedy after study estimates $5.4 billion in potential savings is lost annually because of brand manufacturers using REMS to prevent generic competition.
Not Jazzed About Xyrem REMS, Irish Company Begins Dispute Resolution
Jazz will begin dispute resolution with FDA regarding the risk evaluation and mitigation strategy for its best-selling wakefulness drug.
Narrower Indication, New Studies Are Likely Riffs For Jazz Fibromyalgia Drug
Jazz Pharmaceuticals will likely have to narrow the proposed indication for its fibromyalgia drug JZP-6 (sodium oxybate) following a "complete response" letter from FDA, but that appears to be only the first step for the product.